Cyclopropyl amines as modulators of the histamine H 3 receptor

Details Cyclopropyl amines as modulators of the histamine H 3 receptor Cyclopropyl amines as modulators of the histamine H 3 receptor

2011-03-22

2011-03-22

Habte, Kahsay T (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S060000

Reexamination Certificate

active

07910582

ABSTRACT:
Certain cyclopropyl amines are histamine H3modulators useful in the treatment of histamine H3receptor mediated diseases.

REFERENCES:
patent: 3714179 (1973-01-01), Tweit
patent: 3886160 (1975-05-01), Tweit
patent: 5030644 (1991-07-01), Baldwin et al.
patent: 5098900 (1992-03-01), Mutsukado et al.
patent: 5217986 (1993-06-01), Pomponi et al.
patent: 5352707 (1994-10-01), Pompni et al.
patent: 5464788 (1995-11-01), Bock et al.
patent: 5569659 (1996-10-01), Reitz
patent: 5681954 (1997-10-01), Yamamoto et al.
patent: 5756504 (1998-05-01), Bock et al.
patent: 5869479 (1999-02-01), Kreutner et al.
patent: 5883096 (1999-03-01), Lowe et al.
patent: 5889006 (1999-03-01), Lowe et al.
patent: 5900422 (1999-05-01), Ali
patent: 6596706 (2003-07-01), Kikuchi et al.
patent: 2004/0110746 (2004-06-01), Apodaca et al.
patent: 2007/0066821 (2007-03-01), Allison et al.
patent: 0186817 (1986-07-01), None
patent: 0624584 (1998-08-01), None
patent: 0978512 (2000-02-01), None
patent: 61267560 (1986-11-01), None
patent: 02306237 (1990-12-01), None
patent: HEI 10-59954 (1998-03-01), None
patent: WO 93/04684 (1993-03-01), None
patent: WO 9525443 (1995-09-01), None
patent: WO 9626196 (1996-08-01), None
patent: WO 97 30992 (1997-08-01), None
patent: WO 9805292 (1998-02-01), None
patent: WO 9924475 (1999-05-01), None
patent: WO 99/42458 (1999-08-01), None
patent: WO 02/12190 (2002-02-01), None
patent: WO 02/12214 (2002-02-01), None
patent: WO 02/20500 (2002-03-01), None
patent: WO 02/24695 (2002-03-01), None
patent: WO 02/062784 (2002-08-01), None
patent: WO 02/076925 (2002-10-01), None
patent: WO 03/004480 (2003-01-01), None
patent: WO 03/024928 (2003-03-01), None
patent: WO 03/024929 (2003-03-01), None
patent: WO 03/031432 (2003-04-01), None
patent: WO 03/050099 (2003-06-01), None
patent: WO 03/055866 (2003-07-01), None
patent: WO 03/064411 (2003-08-01), None
patent: WO 03066604 (2003-08-01), None
patent: WO 2004037801 (2004-05-01), None
patent: WO 2005/035534 (2005-04-01), None
patent: WO 2005/040144 (2005-05-01), None
patent: WO 2006/067401 (2006-06-01), None
patent: WO 2008015125 (2008-02-01), None
Aicher, T.D. et al.: “Secondary Amides of ®-3,3,3-Trifluoro-2-hydroxy-2-methylpropionis Acid as Inhibitors of Pyruvate Dehydrogenase Kinase”; J. Med. Chem. 2000, 43: 236-249.
Albengres, E. et al. Systemic Antifungal Agents. Drug Safety (Feb. 1998) 18(2):83-97.
Ali, S.M. et al. Design. Synthesis, and Structure-Activity Relationships of Acetylene-Based Histamine H3 Receptor Antagonists. J. Med. Chem. (1999) 42(5):903-909.
Anjaneyulu, B. et al. Synthesis of 14C-Labelled 1-Methanesulphonyl-3-(1-methyl-5-nitro-1H-imidazol-2-yl)-2-imidazolidinone, (Go 10213). J. Labelled Compd. Radiopharm. (1983) 20(8):951-961.
Apodaca, R. et al. A New Class of Diamine-Based Histamine H3 Receptor Antagonists: 4-(Aminoalkoxy)benzylamines. J. Med. Chem. (2003) 46(18):3938-3944.
Arrang, J.-M. et al. Auto-inhibition of Brain Histamine Release Mediated by a Novel Class (H3) of Histamine Receptor. Nature (Apr. 1983) 302:832-837.
Ash, A.S.F.; Schild, H.O. Receptors Mediating Some Actions of Histamine. Br. J. Pharmac. Chemother. (1966) 27:427-439.
Augustin, M. et al.: Zeitschrift fuer Chemie 1967, 7(10), 389.
Back, D.J.; Tjia, J.F. Inhibition of Tolbutamide Metabolism by Substituted Imidazole Drugs In Vivo: Evidence for a Structure-Activity Relationship. Br. J. Pharmacol. (1985) 85:121-126.
Barbier, A.J. et al.: “Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3antagonist”; British J. of Pharmacology (2004) 143:649-661.
Barn, D.R. et al.: “Synthesis of an Array of Amides by Aluminum Chloride Assisted Cleavage of Resin-Bound Esters”, Tetrahedron Letters, Elsevier Science Publishers, Amsterdam, Netherlands, vol. 37(19): 3213-3216, Apr. 1996.
Barnes, J.C. et al. The Selective Histamine H3 Receptor Antagonist Thioperamide Improves Cognition and Enhances Hippocampal Acetylcholine Release In Vivo. Soc. Neurosci. Abstr. (1993) 19:1813.
Bioworld Today, Mar. 2, 1999, p. 3.
Black, J.W. et al. Definition and Antagonism of Histamine H2-Receptors. Nature (Apr. 1972) 236:385-390.
Celanire, S. et al.: “Histamine H3receptor antagonists reach out for the clinic”; DDT (Dec. 2005) 10(23/24):1613-1627.
Chen, Z.: “Effect of histamine H3-recepor anagonst clobenpropit on spatial memory of radial maze performance in rats”; Acta Pharmacol Sin (2000) 21(10): 905-910.
Ding, Y.-S. et al. Synthesis of High Specific Activity (+)- and (−)-6-[18F]Fluoronorepinephrine via the Nucleophilic Aromatic Substitution Reaction. J. Med. Chem. (1991) 34(2):767-771.
Erdelyi, M.; Gogoll, A. Rapid Homogeneous-Phase Sonogashira Coupling Reactions Using Controlled Microwave Heating. J. Org. Chem. (2001) 66(12):4165-4169.
Fox, G.B. et al.: “Effects of histamine H3receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup”; Behavioural Brain Research 131 (2002): 151-161.
Ganellin, C.R. et al. Synthesis of Potent Non-Imidazole Histamine H3-Receptor Antagonists. Arch. Pharm. Pharm. Med. Chem. (Weinheim, Ger.) (1998) 331:395-404.
Garbarg, M. et al. S-[2-(4-Imidazolyl)ethyl]isothiourea, a Highly Specific and Potent Histamine H3 Receptor Agonist. J. Pharmacol. Exp. Ther. (1992) 263(1):304-310.
Gillaspy, M.L. et al.: “A Simple Method for the Formation of Cyclopropylamines: The First Synthesis of Tricyclopropylamine”; Tetrahedron Letters (1995) 36(41): 7399-7402.
Gliatech Inc. Press Release Nov. 5, 1998.
Gonzalez, F. Garcia, et al. Synthesis of 3-aryl(alkyl)-4-(D-arabino-tetrahydroxybutyl)imidazolin-2-thiones, Carbohydrate Research, 22 (1972): 436-440.
Hancock, A.A.: “The challenge of drug discovery of a GPCR target: Analysis of preclinical pharmacology of histamine H3antagonists/inverse agonists”; Elsevier Biochem. Pharmacology (2006) 71: 1103-1113.
Hirt, R. et al.: Experientia 1961, 17, 418-20.
Ichinose, M.; Barnes, P.J. Histamine H3-Receptors Modulate Nonadrenergic Noncholinergic Neural Bronchoconstriction in Guinea-Pig In Vivo. Eur. J. Pharmacol. (1989) 174(1):49-55.
Iemura, R. et al. Synthesis of Benzimidazole Derivatives as Potential H1-Antihistaminic Agents. J. Heterocycl. Chem. (1987) 24:31-37.
Imamura, M. et al. Unmasking of Activated Histamine H3-Receptors in Myocardial Ischemia: Their Role as Regulators of Exocytotic Norepinephrine Release. J. Pharmacol. Exp. Ther. (1994) 271(3):1259-1266.
Ireland-Denny, L. et al.: “Species-related pharmacological heterogeneity of histamine H3receptors”; Elsevier European J. of Pharmacology 433 (2001): 141-150.
Iwata, R. et al. Synthesis of 3-[1H-Imidazole-4-yl]propyl 4-[18F]fluorobenzyl Ether ([18F]Fuoroproxyfan): A Potential Radioligand for Imaging Histamine H3 Receptors. J. Labelled Compd. Radiopharm. (2000) 43:873-882.
Jarosinski, M.A.; Anderson, W.K. Preparation of Noncondensed 2-Substituted 1-Methylimidazoles via Ipso Substitution Reaction on 2-Sulfinyl or 2-Sulfonyl Derivatives of 4,5-Disubstituted 1-Methylimidazoles. J. Org. Chem. (1991) 56(12):4058-4062.
Jones, R.G. Studies on Imidazoles. II. The Synthesis of 5-Imidazolecarboylates fromGlycine and Substituted Glycine Esters. J. Am. Chem. Soc. (1949) 71:644-647.
Jordaan, A., Arndt, R.R., The Synthesis of 1-Methyl-5-(α-indolyl)imidazole and 1-Methyl-2-ethylthiol-5-(α-indolyl)imidazole. Journal of Heterocyclic Chemistry 5(5), 723-5 (English) 1968.
Kapetanovic, I.M.; Kupferberg, H.J. Nafimidone, an Imidazole Anticonvulsant, and Its Metabolite as Potent Inhibitors of Microsomal Metabolism of Phenytoin and Carbamazepine. Drug Metab. Dispos. (1984) 12(5):560-564.
Korte, A. et al. Characterization and Tissue Distribution of H3 Histamine Receptors in Guinea Pigs by N alpha-Methylhistamine. Biochem. Biophys. Res. Commun. (May 1990) 168(3): 979-986.
Krause, M. et al. Medicinal Chemistry of Histamine H3 Receptor Agonists; In The Histamine H3 Receptor—A Target for New Drugs Leurs, R.; Timmerman, H. (Eds.) Elsevier (1998) 175-196.
Lamberti, C. et al.: “Ant

Affiliated with

Also associated with

Rating

Cyclopropyl amines as modulators of the histamine H 3 receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclopropyl amines as modulators of the histamine H 3 receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclopropyl amines as modulators of the histamine H 3 receptor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2748216